Regeneron Pharmaceuticals, Inc. (RGO.F)
| Previous Close | 975.20 |
| Open | 981.60 |
| Bid | 971.00 x 2800 |
| Ask | 976.00 x 2800 |
| Day's Range | 981.60 - 981.60 |
| 52 Week Range | 628.00 - 1,007.50 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 109.217B |
| Beta (5Y Monthly) | 0.12 |
| PE Ratio (TTM) | 31.06 |
| EPS (TTM) | 31.60 |
| Earnings Date | Aug 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 686.88 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
GlobeNewswireOdronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphomaTARRYTOWN, N.Y., June 28, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odro
